The background to this themed issue on neuropeptides.
A meeting of the British Pharmacological Society in association with the European Neuropeptide Club and Americal Summer Neuropeptide Conference in June 2012 led to this themed issue on neuropetides. A wide range of neuropeptides are discussed, in various physiological and pathophysiological conditions, with respect to their upstream and downstream pathways. It is clear, at this point in time, that targeting neuropeptides has therapeutic potential in pathologies ranging from migraine to obesity. It is also clear from the reviews in this issue of the British Journal of Pharmacology that there is still so much to learn.


BACKGROUND
This article is part of a themed section on Neuropeptides. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.170.issue-7.
Institute of Pharmaceutical Science, King's College London, London, UK.
Julie
J
Keeble
D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D002491:Central Nervous System Agents; D009479:Neuropeptides; D018377:Neurotransmitter Agents
CGRP; GPCR; TRPV1; motilin; neuropeptides; pituitary adenylyl cyclase-activating peptide; substance P; vasoactive intestinal peptide